260 related articles for article (PubMed ID: 18454159)
1. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
Awada A; Albanell J; Canney PA; Dirix LY; Gil T; Cardoso F; Gascon P; Piccart MJ; Baselga J
Br J Cancer; 2008 May; 98(9):1500-7. PubMed ID: 18454159
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer.
Kosmas C; Tsavaris N; Malamos N; Stavroyianni N; Gregoriou A; Rokana S; Polyzos A
Br J Cancer; 2003 Apr; 88(8):1168-74. PubMed ID: 12698179
[TBL] [Abstract][Full Text] [Related]
3. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Lara PN; Koczywas M; Quinn DI; Lenz HJ; Davies AM; Lau DH; Gumerlock PH; Longmate J; Doroshow JH; Schenkein D; Kashala O; Gandara DR
J Thorac Oncol; 2006 Feb; 1(2):126-34. PubMed ID: 17409841
[TBL] [Abstract][Full Text] [Related]
5. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Dreicer R; Petrylak D; Agus D; Webb I; Roth B
Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
Kosmas C; Tsavaris N; Mylonakis N; Tsakonas G; Gassiamis A; Skopelitis H; Polyzos A; Malamos N; Karabelis A
J Chemother; 2007 Jun; 19(3):322-31. PubMed ID: 17594929
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
Bayet-Robert M; Kwiatkowski F; Leheurteur M; Gachon F; Planchat E; Abrial C; Mouret-Reynier MA; Durando X; Barthomeuf C; Chollet P
Cancer Biol Ther; 2010 Jan; 9(1):8-14. PubMed ID: 19901561
[TBL] [Abstract][Full Text] [Related]
9. Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer.
Lortholary A; Delozier T; Monnier A; Bourgeois H; Bougnoux P; Tubiana-Mathieu N; Riffaud JCh; Besson D; Lotz V; Gamelin E
Br J Cancer; 2003 Jun; 88(11):1669-74. PubMed ID: 12771978
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ
Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Campone M; Fumoleau P; Delecroix V; Deporte-Fety R; Perrocheau G; Vernillet L; Borg-Olivier O; Louboutin JP; Bissery MC; Riva A; Azli N
Ann Oncol; 2001 Jul; 12(7):909-18. PubMed ID: 11521794
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Schmid P; Kühnhardt D; Kiewe P; Lehenbauer-Dehm S; Schippinger W; Greil R; Lange W; Preiss J; Niederle N; Brossart P; Freier W; Kümmel S; Van de Velde H; Regierer A; Possinger K
Ann Oncol; 2008 May; 19(5):871-6. PubMed ID: 18209010
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
[TBL] [Abstract][Full Text] [Related]
14. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
[TBL] [Abstract][Full Text] [Related]
15. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
[TBL] [Abstract][Full Text] [Related]
16. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
17. Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen.
Tomasello G; Chiesa MD; Buti S; Brighenti M; Negri F; Rovere RK; Martinotti M; Buononato M; Brunelli A; Lazzarelli S; Donati G; Passalacqua R
Tumori; 2010; 96(1):48-53. PubMed ID: 20437857
[TBL] [Abstract][Full Text] [Related]
18. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Brugnatelli S; Danova M; De Bella MT; Vaglica M; Manuguerra G; Riccardi A; Palmeri S
Oncology; 2002; 62(1):33-8. PubMed ID: 11810041
[TBL] [Abstract][Full Text] [Related]
19. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
Moon YW; Sohn JH; Choi HJ; Chang H; Park BW; Kim SI; Park S; Koo JS; Kim YT; Roh JK; Chung HC; Kim JH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):425-31. PubMed ID: 20012956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
